Bevacizumab — Class II drug recall D-1850-2019
Terminated recall by Pacifico National, Inc. dba AmEx Pharmacy, reported 2019-09-18, distributed in PR. Lack of assurance of sterility.
| Recall number | D-1850-2019 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Pacifico National, Inc. dba AmEx Pharmacy, Melbourne, FL, United States |
| Recall initiated | 2019-08-30 |
| Classified | 2019-09-10 |
| Reported by FDA | 2019-09-18 |
| Terminated | 2020-10-08 |
| Distributed | PR |
| Reason classes | sterility |
Product
Bevacizumab, 1.25 mg/0.05 mL, 31G MJ Syringe Intravitreal Injection, Single use only, Rx only, Repackaged by AmEx Pharmacy 1515 Elizabeth St. Suite J Melbourne, FL 32901
Reason for recall
Lack of assurance of sterility.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1850-2019. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.